KYORIN Pharmaceutical Co., Ltd. - Your health is Kyorin's mission.

Top Message

Kyorin is conducting CSR activities based on its corporate philosophy that continues to fulfill its mission of cherishing life and benefiting society by contributing to better health.

News Release

January 7, 2019

Impact on Kyorin's Financial Performance of MSD's Decision to Voluntarily Recall Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
September 21, 2018

Kyorin Receives Marketing Approval in Japan for｢Beova Tablets 50mg｣ for the Treatment of Overactive Bladder
May 10, 2018

MSD and Kyorin Sign Agreement to Acquires Exclusive Distribution Rights for Therapeutic Agent for Allergic Rhinitis, NASONEX® Nasal
March 29, 2018

Kyorin Pharmaceutical Sign a License Agreement for "SK-1404," a Therapeutic Agent for Nocturia Due to Nocturnal Polyuria
April 11, 2017

Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for Investigational Therapy for Overactive Bladder (Code:KRP-114V) in Asia

About our Business

Kyorin Group

KYORIN Co,.Ltd.

A holding company in charge of planning and promoting of Group-wide management strategies

KYORIN Rimedio Co., Ltd.

Generic drugs,
over-the-counter drugs and others

KYORIN Pharmaceutical Facilities Co., Ltd.

Manufacture and sales of prescription drugs

KYORIN Medical Supply Co., Ltd.

Environmental hygiene, sales promotion, planning and production of advertising